Clinical Trials Browser

Phase 2 × NIH × berzosertib × Clear all

NCT03896503 2026-06-01

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Phase 2 Active not recruiting

104 enrolled 22 charts

Small Cell Lung Carcinoma

NCT03517969 2026-04-23

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

73 enrolled 14 charts

Prostatic Neoplasms

NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

70 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

17 enrolled 14 charts

Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Phase 2 Completed

87 enrolled 13 charts

Metastatic Bladder Urothelial Carcinoma